

Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

THORATEC CARDIOSYSTEMS INC  
Form SC 13D  
February 27, 2001

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

-----

SCHEDULE 13D  
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT  
TO RULE 13d-2(a)

Thoratec Corporation  
-----

(Name of Issuer)

Common Stock, no par value per share  
-----

(Title of Class of Securities)

885175 30 7  
-----

(CUSIP Number)

Seth H. Hoogasian, Esq.  
General Counsel  
(781) 622-1000  
Thermo Electron Corporation  
81 Wyman Street  
Waltham, Massachusetts 02454-9046  
-----

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

February 14, 2001  
-----

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ].

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

(Continued on following pages)

-----  
CUSIP NO. 885175 30 7  
-----

13D

-----  
Page 2 of 8 Pages  
-----

Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

1. NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Thermo Electron Corporation  
04-2209186

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\*

(a) [ ]  
(b) [ ]

3. SEC USE ONLY

4. SOURCE OF FUNDS\*

SC

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM  
2(d) or 2(e) [ ]

6. CITIZENSHIP OR PLACE OF ORGANIZATION  
State of Delaware

NUMBER OF SHARES 7. SOLE VOTING POWER  
BENEFICIALLY 16,686,555  
OWNED BY EACH  
REPORTING PERSON  
WITH

8. SHARED VOTING POWER  
2,731,779

9. SOLE DISPOSITIVE POWER  
19,418,334

10. SHARED DISPOSITIVE POWER  
-0-

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
19,418,334

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES\* [ ]

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
35.5%

Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

14. TYPE OF REPORTING PERSON\*

CO

-----  
\*SEE INSTRUCTIONS BEFORE FILLING OUT!

ITEM 1. Security of the Issuer.

The securities to which this statement relates are the common stock, no par value per share (the "Common Stock"), of Thoratec Corporation (formerly known as Thoratec Laboratories Corporation), a California corporation (the "Company"). The principal executive offices of the Company are located at 6035 Stoneridge Drive, Pleasanton, California 94588.

ITEM 2. Identity and Background.

This statement is being filed by Thermo Electron Corporation, a Delaware corporation ("Thermo Electron"). Thermo Electron is sometimes referred to herein as the "Reporting Person."

The principal business address and principal office address of the Reporting Person is 81 Wyman Street, Waltham, Massachusetts 02454-9046.

The Reporting Person is a leading provider of analytical and monitoring instruments used in a broad range of applications, from life sciences research to telecommunications to food, drug, and beverage production.

Appendix A attached to hereto sets forth with respect to each executive officer and director of the reporting Person the following information:

- (a) name;
- (b) business address;
- (c) present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted; and
- (d) citizenship.

To the knowledge of the Reporting Person, there is no person who may be deemed to be a controlling person of the Reporting Person.

During the last five years, neither the Reporting Person nor, to the knowledge of the Reporting Person, any executive officer or director of the Reporting Person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

During the last five years, neither the Reporting Person nor, to the knowledge of the Reporting Person, any executive officer or director of the Reporting Person has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

ITEM 3. Source and Amount of Funds or Other Consideration.

The Common Stock acquired by the Reporting Person was acquired on February 14, 2001, in connection with the merger (the "Merger") of Lightning Acquisition Corp., a Massachusetts corporation and wholly owned subsidiary of the Company ("Merger Sub"), with and into Thermo Cardiosystems Inc., a Massachusetts

## Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

corporation ("Cardiosystems"), pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2000, by and among the Company, Merger Sub, Cardiosystems and the Reporting Person. The Merger Agreement is filed as Exhibit 99.1 hereto. Prior to the Merger, the Reporting Person was the majority stockholder of Cardiosystems.

Pursuant to the terms of the Merger Agreement, each outstanding share of Cardiosystems common stock was converted into the right to receive 0.835 shares of Common Stock of the Company. Accordingly, the outstanding shares of Cardiosystems common stock owned by the Reporting Person were converted into the number of shares of Common Stock of the Company acquired by the Reporting Person on February 14, 2001.

### ITEM 4. Purpose of Transactions.

The following is a summary of the principal terms of the transaction. This summary is qualified in its entirety by reference to the definitive agreements referred to herein and filed as exhibits hereto.

The Merger Agreement was entered into by the Company, Merger Sub, Cardiosystems and the Reporting Person as of October 3, 2000. The closing of the Merger occurred on February 14, 2001. In connection with the Merger, the former stockholders of Cardiosystems received, in the aggregate, 32,213,812 shares of Common Stock of the Company.

In connection with the Merger Agreement, and as a condition to the consummation of the Merger, the Company and the Reporting Person entered into (i) a Shareholder Agreement, dated October 3, 2000 (the "Shareholder Agreement"), which is attached hereto as Exhibit 99.2 and (ii) a Registration Rights Agreement, dated October 3, 2000 (the "Registration Rights Agreement"), which is attached hereto as Exhibit 99.3.

Pursuant to the Shareholder Agreement, the Company agreed that, following the Merger, as long as the Reporting Person beneficially owns voting securities of the Company representing at least 10% of the voting power of all of the Company's voting securities outstanding, the Company will take all necessary action to cause a nominee of the Reporting Person to be elected to the Company's board of directors. The Reporting Person has designated its Chief Financial Officer, Theo Melas-Kyriazi, to serve as its initial representative on the Company's board of directors. Additionally, the Reporting Person agreed that, so long as it beneficially owns voting securities of the Company representing at least 5% of the voting power of all of the Company's voting securities outstanding, the Reporting Person will not (i) acquire any voting securities of the Company without prior consent of the board of directors of the Company, (ii) sell or otherwise transfer any shares of Common Stock of the Company received in the Merger prior to the date four months following the consummation of the Merger, (iii) sell or otherwise transfer more than 25% of the shares of Common Stock of the Company received in the Merger prior to the first anniversary of the consummation of the Merger, (iv) sell or otherwise transfer more than 50% of the shares of Common Stock of the Company received in the Merger prior to the date eighteen months following the consummation of the Merger, or (v) sell or transfer any shares of Common Stock of the Company in privately negotiated transactions if, after giving effect to such transactions, the transferee would own securities of the Company representing more than 10% of the voting power of all of the Company's voting securities outstanding. The Reporting Person also agreed that, with respect to the Common Stock of the Company it received in the Merger, it will (i) cause such shares of Common Stock to appear or otherwise be counted as present for purposes of establishing a quorum at any shareholder meeting of the Company and (ii) provide the Company's management with a proxy or consent to vote such shares of Common Stock owned by the Reporting Person, but not more than a number of shares representing 5% of the voting power of

## Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

securities of the Company outstanding at the closing of the Merger.

Pursuant to the terms of the Registration Rights Agreement, the Company agreed to (i) file with the Securities and Exchange Commission (the "SEC") and use its reasonable best efforts to cause to become effective an 'evergreen' or 'shelf' registration statement registering for resale by the Reporting Person the Common Stock of the Company received by the Reporting Person in the Merger, (ii) file a registration statement, or a post-effective amendment to the shelf registration statement, for an underwritten offering of the shares of Common Stock of the Company received by the Reporting Person in the Merger at various times, and (iii) provide the Reporting Person the right to include the shares of Common Stock of the Company received by the Reporting Person in the Merger in any registration statement filed by the Company with the SEC, other than registration statements relating to employee plans and acquisitions. The timing of the effectiveness of the 'shelf' registrations corresponds to the timing of the lapse of the transfer restrictions under the Shareholder Agreement applicable to the shares of Common Stock of the Company received by the Reporting Person in the Merger.

Additionally, the Reporting Person has granted certain officers, directors and employees of the Reporting Person options to purchase a total of 68,000 shares of Cardiosystems common stock owned by Thermo Electron before the Merger. Those officers, directors and employees are entitled to have the Company register the shares of Common Stock of the Company into which those Cardiosystems shares were converted in the Merger.

Immediately prior to the consummation of the Merger, Cardiosystems had \$54.9 million of 4 3/4% Subordinated Convertible Debentures due 2004 (the "4 3/4% Debentures") outstanding. The 4 3/4% Debentures were convertible into shares of Cardiosystems common stock at a price of \$31.415 per share of Cardiosystems common stock. Following the consummation of the Merger, the 4 3/4% Debentures remain obligations of Cardiosystems, but are convertible into shares of Common Stock of the Company, at a conversion price of \$37.623 per share, which is \$31.415 divided by the 0.835 merger exchange ratio.

Additionally, the 4 3/4% Debentures are guaranteed by the Reporting Person, which guarantee remains in effect after the Merger. Cardiosystems has agreed to reimburse the Reporting Person for any payments made by the Reporting Person under such guarantee. Pursuant to the terms of the Merger Agreement, the Company has obtained a standby letter of credit in the amount of \$45 million to support the repayment of the 4 3/4% Debentures and to reduce the prospect that the Reporting Person will be required to pay any amount under its guarantee of the 4 3/4% Debentures.

As previously announced in January 2000, the Reporting Person has initiated a restructuring, of which the Merger is a component, to focus on its core instruments business. Accordingly, the Reporting Person may consummate the sale of shares of Common Stock from time to time in accordance with the Shareholder and Registration Rights Agreements. Any such sales will be dependent upon then current market conditions and other relevant considerations, and may be made on the open market, in privately negotiated transactions or in one or more underwritten offerings. Except as described in this Item 4, the Reporting Person does not have any current plans or proposals that relate to or would result in any of the events described in paragraphs (a) through (j) of Item 4 of Schedule 13D.

### ITEM 5. Interest in Securities of the Issuer.

(a) As a result of the Merger, the Reporting Person is the beneficial owner of 19,418,334 shares of Common Stock of the Company, representing approximately 35.5% of the outstanding Common Stock of the Company. This

## Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

percentage amount reflects the 32,213,812 shares of Common Stock of the Company issued in connection with the Merger, as disclosed by the Company in its registration statement on Form S-4 (Commission File No. 333-49120). Of the 19,418,334 shares of Common Stock owned by the Reporting Person, (i) to the knowledge of the Reporting Person, 65,506 shares of Common Stock are beneficially owned by the other persons named in Item 2, (ii) 56,780 shares of Common Stock are subject to options to acquire such shares granted by the Reporting Person pursuant to its director and employee stock option plans, (iii) 39,869 shares of Common Stock are issuable upon the conversion by the Reporting Person of \$1,500,000 principal amount of the 4 3/4% Debentures held by it, and (iv) Reporting Person has agreed to grant 16,700 shares of Common Stock to a former officer of Cardiosystems pursuant to a transition agreement executed with such former officer. Information with respect to the beneficial ownership of the shares of Common Stock of the other persons named in Item 2 is set forth in Appendix A. Except as set forth in this Item 5, to the best knowledge of the Reporting Person, none of the parties named in Item 2 owns any of the Company's Common Stock.

(b) With respect to 2,731,779 shares of Common Stock of the Company beneficially owned by the Reporting Person, the Reporting Person shares the power to vote all of such shares with the Company pursuant to the Shareholder Agreement, as more fully described in Item 4 above. With respect to the remainder of the shares of Common Stock of the Company beneficially owned by the Reporting Person, the Reporting Person has the sole power to vote all such shares. Subject to the terms of the Shareholder Agreement, as more fully described in Item 4 above, the Reporting Person has the sole power to dispose of the shares of Common Stock beneficially owned by it. With respect to the shares of Common Stock of the Company beneficially owned by the other persons named in Item 2, except as set forth in Appendix A, each such person has the sole power to vote all of such shares and the sole power to dispose of all of such shares.

Item 1 sets forth the Company's name and state of incorporation along with the address of its principal business and principal office. The Company's principal business is the research, development, manufacturing and marketing of medical devices for circulatory support and vascular graft applications. To the best knowledge of the Reporting Person, during the last five years, the Company (i) has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) and (ii) was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as result of which it was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.

(c) Except as described above in this Item 5 and in Item 4, which item is incorporated herein by reference, neither the Reporting Person nor, to the knowledge of the Reporting Person, any person named in Appendix A beneficially has effected any transactions in Common Stock during the past 60 days.

(d) None.

(e) Not applicable.

ITEM 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

The responses to Item 3, Item 4, Item 5, the Merger Agreement, the Shareholder Agreement and the Registration Rights Agreement are incorporated herein by reference.

Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

ITEM 7. Material to be Filed as Exhibits.

The following documents are filed as a Exhibits to this Schedule 13D.

Exhibit No.	Description
99.1	Agreement and Plan of Merger, dated as of October 3, 2000, by and among Thoratec Laboratories Corporation, Lightning Acquisition Corp., Thermo Cardiosystems Inc. and Thermo Electron Corporation (1)
99.2	Shareholder Agreement, dated as of October 3, 2000, by and between Thoratec Laboratories Corporation and Thermo Electron Corporation.
99.3	Registration Rights Agreement, dated as of October 3, 2000, by and between Thoratec Laboratories Corporation and Thermo Electron Corporation.

-----  
 (1) Incorporated by reference from the Registration Statement on form S-4 (File No. 333-49120) of Thoratec Corporation.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 23, 2001

THERMO ELECTRON CORPORATION

By: /s/ Theo Melas-Kyriazi

-----  
 Name: Theo Melas-Kyriazi  
 Title: Vice President and Chief Financial Officer

APPENDIX A

Thermo Electron Corporation

The name, present principal occupation or employment and beneficial ownership of shares of common stock of Thoratec Corporation (the "Company") of each director and executive officer of Thermo Electron Corporation ("Thermo Electron") is set forth below. Unless otherwise noted, all such individuals are citizens of the United States. Unless otherwise noted, the business address of each executive officer and director of Thermo Electron is 81 Wyman Street, Waltham, Massachusetts 02454-9046.

Directors

-----

Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

		Beneficial Ownership of Shares of the Company Common Stock	
Name/Present Principal Occupation or Employment	Business Address	Shares Held Outright	Shares Underlying Options Exercisable Prior to April 15, 2001
Samuel W. Bodman Chairman and Chief Executive Officer of Cabot Corporation.	Cabot Corporation 75 State Street Boston, Massachusetts 02109	0	0
Peter O. Crisp Vice Chairman of Rockefeller Financial Services, Inc.		0	0
Elias P. Gyftopoulos Professor Emeritus of the Massachusetts Institute of Technology.	Massachusetts Institute of Technology Room 24-109 77 Massachusetts Avenue Cambridge, Massachusetts 02139	11,192	3,131
Frank Jungers Private consultant on business and energy matters.	822 NW Murray Suite 242 Portland, Oregon 97229	10,229	835
Jim P. Manzi Currently involved in number of technology startup ventures, primarily relating to the Internet.		0	0
Robert A. McCabe Chairman of Pilot Capital Corporation.	Pilot Capital Corporation 444 Madison Avenue Suite 2103 New York, New York 10022	9,394	835
Robert W. O'Leary President and Chief Executive Officer of PacifiCare Health Systems Inc.	PacifiCare Health Systems, Inc. 3120 Lake Center Drive Santa Ana, California 92704	0	0
Hutham S. Olayan President and director of Olayan America Corporation.	Suite 1100 505 Park Avenue New York, New York 10022	9,394	835
Richard F. Syron Chief Executive Officer and Chairman of the Board of Thermo Electron		0	0
Marijn E. Dekkers(1) President, Chief Operating Officer and		0	0



Edgar Filing: THORATEC CARDIOSYSTEMS INC - Form SC 13D

Director of Thermo  
Electron

(1) Mr. Dekkers is a citizen of The Netherlands

Executive Officers Who are Not Directors

No person is a controlling stockholder of Thermo Electron.

Name/Present Principal Occupation or Employment	Business Address	Beneficial Ownership of Shares of the Company Common Stock	
		Shares Held Outright	Shares Underlying Options Exercisable Prior to April 15, 2001
Theo Melas-Kyriazi (2) Vice President and Chief Financial Officer of Thermo Electron		2,961	16,700
Guy Broadbent Vice President, Optical Technologies of Thermo Electron		0	0
Barry S. Howe Vice President, Measurement and Control of Thermo Electron		0	0
Colin Maddix Vice President, Life Sciences of Thermo Electron		0	0
Seth H. Hoogasian Vice President and General Counsel of Thermo Electron		0	0
Peter E. Hornstra Corporate Controller and Chief Accounting Officer of Thermo Electron		0	0
All directors and current executive officers as a group		43,170	22,336

(2) Mr. Melas-Kyriazi is a citizen of Greece.